These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17612757)

  • 1. Special report on the Sanofi-Aventis cardiometabolic symposium.
    Cardiovasc J Afr; 2007; 18(3):192-5, 198-200, 202. PubMed ID: 17612757
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiometabolic risk modification: current trends and emerging therapies.
    Lillo JL; Bray G; Woods SC; Henry RR; Hadley RD
    JAAPA; 2006 Dec; Suppl Cardiometabolic():3-14; quiz 15-6. PubMed ID: 17354517
    [No Abstract]   [Full Text] [Related]  

  • 3. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention.
    Ahmed MH
    Saudi Med J; 2007 May; 28(5):806-8. PubMed ID: 17457461
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S; Gupta BM
    Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular diabetology: clinical, metabolic and inflammatory facets. Preface.
    Fisman EZ; Tenenbaum A
    Adv Cardiol; 2008; 45():xi-xiii. PubMed ID: 18409234
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease under the influence of excess visceral fat.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.
    Ridker PM
    Circulation; 2003 Sep; 108(12):e81-5. PubMed ID: 14504253
    [No Abstract]   [Full Text] [Related]  

  • 15. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New obesity and metabolic syndrome treatment: rimonabant].
    Makoundou V; Golay A
    Rev Med Suisse; 2006 Jan; 2(47):41-5. PubMed ID: 16465944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of metabolic syndrome.
    Oda E
    Stroke; 2007 Nov; 38(11):e152. PubMed ID: 17872479
    [No Abstract]   [Full Text] [Related]  

  • 19. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.